MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road,

Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 31580

Fax: 00 91 (22) 2202 4657 E-mail: info@amphray.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

Ref No: TPL PP 200633 2020; 20th August, 2020

TRIO

CHEM

To

BSE Limited

Corporate Relationship Department,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

<u>Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015</u>

Pursuant to Notice of Board meeting dated 8th August, 2020 the Board meeting was held on today Thursday, 20th August, 2020 at 2.00 p.m. at 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

- The Board approved the Unaudited Financial Results for the quarter ended on 30th June, 2020, as reviewed by the Audit Committee, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- The Board noted and took on records the Limited Review Report for the quarter ended on 30th June,
 2020 as placed before the Board.
- 3. Take notes on the compliance for the quarter ended 30th June, 2020
- 4. Board Meeting commenced at 2.00 p.m. and concluded at 2.25 p.m.

You are requested to take note of the same.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR

DIN: 00312369

Place: Mumbai



Kanu Doshi Associates LLP

Chartered Accountants

Mumbai Address : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T : 022-2615 0100 / 111 / 112 • F : 022 2615 0113

Pune Address: 123, Sohrab Hall, 21 Sassoon Road,
Opp. Jehangir Hospital, Pune - 411001 • T: 020 4906 7177

E: info@kdq.co.in • W: www.kdq.co.in

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To, The Board of Directors of TRIOCHEM PRODUCTS LIMITED

- We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("The Company") for the quarter ended June 30, 2020 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP Chartered Accountants

Firm Registration No: 104746W/W100096

KUNAL SUMANT VAKHARIA Cightify region is BLTSAL SCHALL'S SCHALL S

Kunal Vakharia

Partner

Membership No.: 148916 UDIN: 20148916AAAADL7063

Place: Mumbai

Date: 20th August 2020



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001.

Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphrav.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

	(Rs. in lakhs) Except				s) Except EPS
Sr	Particulars Particulars		Year Ended		
No		30-06-2020	31-03-2020	30-06-2019	31-03-2020
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
l	Income				
	(a) Revenue from Operations		1,147.66	52.60	2,003.18
	(b) Other income	1.30	33.38	0.16	46.63
	Total Income from operations	1.30	1,181.04	52.76	2,049.81
2	Expenses:				
	(a) Cost of materials consumed	418.48	544.16	-	968.86
	(b) Purchase of stock-in-trade		32.77		37.55
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	(424.31)	251.69	35.90	354.67
	(d) Employee benefits expenses	16.89	30.41	15.52	82.33
	(e) Finance costs	2.09	5.78	5.16	22.97
	(f) Depreciation and amortisation expense	3.42	4.11	4.16	16.68
	(g) Other expenses	20.04	26.64	30.93	111.57
	Total Expenses	36.61	895.56	91.67	1,594.63
	Total Miperior				
3	Profit / (Loss) from ordinary activities before exceptional items (1-2)	(35.31)	285.48	(38.91)	455.18
í	Exceptional items	-). .	-	
5	Profit / (Loss) before tax (3 +/- 4)	(35.31)	285.48	(38.91)	455.18
6	Tax expense				
	- Current tax	0.02	73.31		117.33
	- Deferred tax	(8.83)	(0.63)	(10.78)	(2.43
	Total Tax expenses	(8.81)	72.68	(10.78)	114.90
7	Profit / (Loss) for the period (5 +/- 6)	(26.50)	212.80	(28.13)	340.28
8	Other comprehensive income, net of income tax				
	A. (i) Items that will be reclassified to profit or Loss				-
	(ii) Income tax relating to items that will be reclassified to profit or loss			-	-
	B. (i) Items that will not be reclassified to profit or Loss	0.11	0.02	0.01	(0.30
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.03)	-0.00	(0.01)	0.08
	Total Other comprehensive income, net of income tax	0.09	0.02		(0.22
9	Total Comprehensive income for the period (8 +/- 7)	(26.42)	212.82	(28.13)	340.06
10	Paid-up equity share capital (Face value of Rs10/- per share)	24.50	24.50	24.50	24.50
					1 102 17
11	Reserve excluding Revalution Reserves as per balance sheet of previous				1,193.14
	accounting year				
12	Earning per share (EPS) (of Rs.10/- each) (not annualised)		06.06	/11 /0	120.00
	Basic / Diluted EPS	(10.82)	86.86	(11.48)	138.89

Notes:

The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).



The above unaudited financial results of the Company for the quarter ended June 30, 2020 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 20.08.2020

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001.

Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: info@amphray.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

- The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- The figure for quarter ended 31st March, 2020 are the balancing figures between audited figures of the full financial year 31st March, 2020 and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter ended 30th June, 2020.
- The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU SITARAM Digitally signed by RAMU

by RAMU SITARAM DEORA

RAMU S. DEORA DIRECTOR & CEO

DIN: 00312369

Dated: 20th August, 2020



Place: Mumbai

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001

website: www.triochemproducts.com CIN: L24249MH1972PLC015544

(Rs. in lakhs) Except EPS

RACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 3	OTH JUNE 202	20		
Particulars	For the	For the	For the	For the Year
	Quarter	Quarter	Quarter	Ended on
	Ended on	Ended on	Ended on	
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	Audited	Unaudited	Unaudited	Audited
Total Income from operations	1.30	1,181.04	52.76	2,049.81
Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	(35.31)	285.48	(38.91)	455.18
Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	(35.31)	285.48	(38.91)	455.18
Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	(26.50)	212.80	(28.13)	340.28
	0.09	0.02	•	(0.22)
·	24.50	24.50	24.50	24.50
				1,193.14
	(10.82)	86.86	(11.48)	138.89
b) Diluted (not annualized)	(10.82)	86.86	(11.48)	138.89
	Particulars Total Income from operations Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs.10/- per share) Other Equity Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) a) Basic (not annualized)	Particulars Particulars For the Quarter Ended on 30-Jun-20 Audited Total Income from operations Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs. 10/- per share) Other Equity Earnings per share (of Rs. 10/- each) (for continuing and discontinued operations) a) Basic (not annualized) (10.82)	Quarter Ended on 30-Jun-20 Audited Unaudited Total Income from operations Total Income from operations Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs.10/- per share) Other Equity Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) a) Basic (not annualized) (10.82) 86.86	Particulars Parti

Notes:

- 1) The above unaudited financial results of the Company for the quarter ended June 30,2020 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 20.08.2020
- 2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals, the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The figure for quarter ended 31st March, 2020 are the balancing figures between audited figures of the full financial year 31st March, 2020 and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 5) The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter ended 30th June,
- 6) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever
- 7) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

RAMU SITARAM Digitally signed **DEORA**

by RAMU SITARAM **DEORA**

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369

Place: Mumbai Dated: 20th August, 2020

